Janus Henderson Group PLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Janus Henderson Group PLC acquired a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 236,116 shares of the company’s stock, valued at approximately $5,840,000. Janus Henderson Group PLC owned 19.51% of Oruka Therapeutics at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Braidwell LP purchased a new stake in Oruka Therapeutics during the third quarter worth $12,640,000. Great Point Partners LLC purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $12,614,000. FMR LLC purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $114,763,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at about $1,037,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ORKA shares. Lifesci Capital started coverage on Oruka Therapeutics in a research report on Monday, September 16th. They set an “outperform” rating and a $41.00 price target on the stock. Leerink Partners began coverage on shares of Oruka Therapeutics in a research note on Tuesday, September 17th. They issued an “outperform” rating and a $44.00 price target on the stock. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Finally, TD Cowen started coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They set a “buy” rating for the company. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Oruka Therapeutics presently has an average rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA opened at $23.01 on Tuesday. The firm has a market capitalization of $805.35 million, a PE ratio of -3.67 and a beta of 0.78. Oruka Therapeutics, Inc. has a 52 week low of $18.20 and a 52 week high of $53.88. The firm has a 50-day simple moving average of $25.28.

Oruka Therapeutics Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.